Anlon Healthcare
August 26, 2025 – August 29, 2025
| Price | ₹86 - ₹91 |
| Premium | ₹0 |
|---|---|
| Lot size | 164 |
| Allotment | Sep 1, 2025 |
| Listing | Sep 3, 2025 |
Anlon Healthcare About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 164 | 14924 | 8110 |
| sHNI | 14 | 2296 | 208936 | 290 |
| bHNI | 68 | 11152 | 1014832 | 579 |
IPO Details
| Total Issue Size | 1,33,00,000 shares (aggregating up to ₹121.03 Cr) |
| Fresh Issue | 1,33,00,000 shares (aggregating up to ₹121.03 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,98,51,500 shares |
| Share Holding Post Issue | 5,31,51,500 shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 75% of the Net Issue |
| Retail Shares Offered | Not less than 10% of the Offer |
| NII Shares Offered | Not less than 15% of the Net Isssue |
Key Performance Indicator (KPI)
Details will be added soonCompany Financial ( In ₹ Crore)
Details will be added soon
Peer Comparison
Details will be added soon
About Company
- Established in 2013, Anlon Healthcare Limited is engaged in the manufacturing of pharma intermediates and active pharmaceutical ingredients (APIs).
- Products are widely used in medicines, nutraceuticals, personal care, and veterinary health.
Product Standards & Compliance:
- Manufacturing is carried out in line with Indian and international pharmacopeia standards including IP, BP, EP, JP, and USP.
- Focus on high-purity outputs, with processes designed to minimize impurities.
Custom Manufacturing Capabilities:
- Offers custom chemical manufacturing services for complex requirements.
- Provides solutions tailored to meet specific purity and formulation needs of global customers.
Regulatory Approvals & Filings:
- Received Drug Master File (DMF) approvals from ANVISA (Brazil), NMPA (China), and PMDA (Japan) for Loxoprofen Sodium Dihydrate and Loxoprofen Acid APIs.
- Filed 21 DMFs with various global authorities.
- Currently preparing filings for Ketoprofen and Dexketoprofen Trometamol approvals.
Product Portfolio:
- 65 commercialized products.
- 28 products at the pilot stage.
- 49 products under laboratory testing.
Quality & R&D:
- Quality is ensured through rigorous testing, analysis, and continuous process improvements.
- Supported by 4 advanced laboratories.
- Backed by a 34-member technical team, including 24 science graduates, ensuring strong R&D and quality compliance.
Strength
Strong Promoters & Experienced Management: Led by dedicated promoters and a skilled management team, driving strategies, innovation, diversification, and customer-focused growth since inception.
High Entry & Exit Barriers: Long customer approval cycles and strict domestic & international standards create strong entry barriers, ensuring consistent demand and limited competition.
Robust In-House Quality Control: Backed by four advanced testing labs, the company ensures rigorous quality checks, process optimization, and compliance with customer and industry standards.
Weakness
Stringent Quality Compliance: Failure to meet strict technical specifications, inspections, and audits may lead to order cancellations, warranty claims, and loss of business.
Customer Concentration Risk: Revenue depends on a limited number of customers; losing any major client could significantly impact financial performance and cash flows.
Dependency on Pharma Industry Demand: Major revenue comes from pharma sector sales; reduced demand or new alternate drugs could adversely affect business growth and profitability.
Anlon Healthcare Lead Manager(s)
Anlon Healthcare Address
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/